International Journal of Drug Policy最新文献

{"title":"Harmonizing cannabis and environmental policy","authors":"Evan Mills","doi":"10.1016/j.drugpo.2025.104923","DOIUrl":"10.1016/j.drugpo.2025.104923","url":null,"abstract":"<div><div>Policy fragmentation contributes to the myriad environmental impacts of the cannabis industry and impedes solutions. Examination of how this plays out in the context of the US provides real-world examples, further complicated by the lack of a robust overarching federal policy framework. A key determinant of environmental problems is whether cannabis cultivation is conducted indoors (greenhouses or windowless plant factories) or outdoors in open fields. For example, emissions of greenhouse gases are ∼100-times greater for indoor cultivation, and water use is higher when accounting for water associated with power production. Other distinct spheres of impact involve land use, waste production, air pollution, ecosystem degradation, and adverse indoor environmental quality conditions faced by workers. Some consequences are differentially burdensome for marginalized populations, suggesting an overlay of environmental justice considerations. Relevant but uncoordinated regulatory entities include those focused formally on cannabis regulation, law enforcement, energy supply and demand, building codes, air quality, climate change, water supply and quality, waste management, fish and wildlife, occupational safety, public health, and urban planning. While criminalization has contributed to environmental concerns, both legal and illicit operations are problematic. Cannabis legalization enables improved policy coordination, but is not a panacea or intrinsic solution. The potential for policymaker collaboration and regulatory coordination includes removing barriers to improved practices and, in particular, providing incentives for lower-impact outdoor cultivation. However, politics often stands as an impediment to otherwise pragmatic policy solutions.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"143 ","pages":"Article 104923"},"PeriodicalIF":4.4,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144662153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peer-delivered mail-order self-collection and linkage to treatment for hepatitis C virus infection among users of a harm reduction service in Denmark","authors":"Jonas Demant ,&nbsp;Stephen Strunge Nilsson ,&nbsp;Louise Krohn-Dehli ,&nbsp;Anne Øvrehus ,&nbsp;Lone Hagens Mygind ,&nbsp;Lone W. Madsen ,&nbsp;Jacob Søholm ,&nbsp;Jeffrey V. Lazarus ,&nbsp;Jannet van der Veen ,&nbsp;Nina Weis","doi":"10.1016/j.drugpo.2025.104919","DOIUrl":"10.1016/j.drugpo.2025.104919","url":null,"abstract":"<div><h3>Background</h3><div>Hepatitis C virus infection remains a major public health challenge, particularly among people who inject drugs. Despite the availability of highly effective direct-acting antiviral treatment, many remain undiagnosed and untreated. Self-collection for hepatitis C may improve testing uptake in this marginalized population. This study evaluated a peer-assisted, mail-based self-collection model integrated into a harm reduction service in Denmark.</div></div><div><h3>Methods</h3><div>This prospective observational study was conducted from June 2023 to December 2024. Participants were recruited through a peer-led mail-order harm reduction program operated by the non-governmental organization User’s Academy in Copenhagen. Self-collection kits with a dried blood spot finger-prick test were mailed to participants, with peer support provided throughout the care cascade. The primary outcome was the proportion returning the collected sample, and receiving results. Secondary outcomes included assistance with testing, HCV detection, treatment initiation, and cure. Factors associated with test completion were analyzed using adjusted odds ratios.</div></div><div><h3>Results</h3><div>A total of 126 participants were enrolled (median age 44 years; 29 percent women). Forty-four percent completed self-collection and received results; 52 percent of these received assistance. Among completers, 7 percent had detectable hepatitis C virus RNA, and all initiated treatment. Completion was associated with age 40 or older (adjusted odds ratio 3.31, 95 % confidence interval: 1.02 to 11.90) and enrollment in opioid agonist treatment (adjusted odds ratio 3.70, 95 % confidence interval: 0.99 to 15.70). Stimulant use (adjusted odds ratio 0.23, 95 % confidence interval: 0.05 to 0.88) and previous hepatitis C testing (adjusted odds ratio 0.18, 95 % confidence interval: 0.03 to 0.77) were associated with lower completion.</div></div><div><h3>Conclusion</h3><div>A peer-assisted, mail-based hepatitis C self-collection model is feasible and may improve testing and treatment uptake among people who inject drugs.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"143 ","pages":"Article 104919"},"PeriodicalIF":4.4,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144653204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing intersystem and community values to enhance opioid use disorder treatments: Communities That Heal intervention in New York","authors":"Dean Rivera ,&nbsp;Anindita Dasgupta ,&nbsp;Allyson G. Cogan ,&nbsp;Mary Bartkus ,&nbsp;Elwin Wu ,&nbsp;Aimee N.C. Campbell ,&nbsp;Nabila El-Bassel","doi":"10.1016/j.drugpo.2025.104922","DOIUrl":"10.1016/j.drugpo.2025.104922","url":null,"abstract":"<div><h3>Background</h3><div>In response to rising overdose deaths, the State of New York established multisystem coalitions in 16 counties to tackle the opioid crisis. These coalitions brought together stakeholders from various systems, including healthcare, behavioral health, criminal justice, and community-based services to address the epidemic in a coordinated community driven approach. The literature shows the implementation of effective, evidence-based community interventions is often hindered by differing values (attitudes, beliefs, and norms) between stakeholders of these coalitions and the communities where evidence-based approaches are implemented. This paper investigates how these divergent or shared values affect the implementation of naloxone and medications for opioid use disorder interventions.</div></div><div><h3>Methods</h3><div>We conducted a thematic analysis of semistructured interviews (<em>n</em> = 43) with coalition members representing multiple systems across eight New York counties. The analysis was guided by Interorganizational Relations and Resource Dependence Theories to examine how differing or shared values influenced the implementation of community-based opioid use disorder interventions.</div></div><div><h3>Results</h3><div>Five themes emerged on how divergent or shared intersystem and community values affected OUD interventions: a) shared values among coalition systems, b) divergent values between coalition systems, c) community education and destigmatization efforts, d) moral culpability of people who use opioids (PWUO), and e) value judgments of moral worthiness.</div></div><div><h3>Conclusions</h3><div>Aligning values across systems and communities is crucial for effectively implementing community-based interventions aimed at combating the opioid epidemic. Shifting systemic and community narratives from value judgments of moral worthiness and the moral culpability of PWUO to recognizing OUD as a chronic health disorder is key to achieving this alignment. Central to this effort are community education and destigmatization campaigns, which play a pivotal role in promoting a unified multisystem-community approach.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"143 ","pages":"Article 104922"},"PeriodicalIF":4.4,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144653202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Stigma is our most powerful enemy”: Understanding opioid use disorder stigma and the role of peer support in rural Maryland","authors":"M.S. Anvari ,&nbsp;C.A. Sacko ,&nbsp;G.E. Atkinson ,&nbsp;N.S. Triplett ,&nbsp;M.W. Kihiuria ,&nbsp;M.S. Sonn ,&nbsp;J.S. Anane ,&nbsp;M. Derenoncourt ,&nbsp;A.M. Belcher ,&nbsp;E. Weintraub ,&nbsp;S.M. Kattakuzhy ,&nbsp;J.F. Magidson","doi":"10.1016/j.drugpo.2025.104924","DOIUrl":"10.1016/j.drugpo.2025.104924","url":null,"abstract":"<div><h3>Introduction</h3><div>Rural areas of the U.S. face persistent challenges with opioid-related fatalities and opioid use disorder (OUD) treatment retention. One significant barrier is stigma surrounding OUD and its treatment. Rural areas may face unique structural and geospatial stigmas that impact OUD and care. Peer recovery specialists (PRSs), individuals with lived substance use and recovery experience, may offer support in overcoming stigma-related barriers to recovery in these areas, yet little is known about if and how PRSs can support these efforts. This qualitative study aimed to understand: 1) how multiple levels of stigmas manifest amongst patients receiving OUD treatment in an innovative telemedicine rural mobile treatment unit; 2) how stigmas influence treatment experiences; and 3) if and how PRS engagement may ameliorate stigma-related barriers.</div></div><div><h3>Methods</h3><div>Semi-structured interviews were conducted with 25 patients and 5 staff members, and transcripts were analyzed using inductive thematic analysis.</div></div><div><h3>Findings</h3><div>Findings demonstrated the pervasive impact of multiple stigmas (e.g., OUD, polysubstance use, and other identity-related stigmas), enacted by numerous sources (e.g., pharmacists, family, physicians), on OUD treatment initiation and outcomes. These were uniquely influenced by rural living conditions, including low access to alternative healthcare options, the small, insular social environment, limited privacy, and reluctance to help-seeking. Participants expressed that, through their shared lived experience, PRSs can help patients overcome stigma through increased trust and rapport, teaching coping strategies, and instilling hope.</div></div><div><h3>Conclusions</h3><div>Understanding rural patient experiences with multi-layered stigmas is crucial for developing innovative strategies to reduce stigma and support recovery.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"143 ","pages":"Article 104924"},"PeriodicalIF":4.4,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144653203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preferences for Pre-exposure Prophylaxis (PrEP) among people who use drugs in Thailand: A discrete choice experiment","authors":"Ajaree Rayanakorn ,&nbsp;Piyameth Dilokthornsakul ,&nbsp;Donsuk Pongnikorn ,&nbsp;Jason J. Ong ,&nbsp;Warittha Tieosapjaroen","doi":"10.1016/j.drugpo.2025.104913","DOIUrl":"10.1016/j.drugpo.2025.104913","url":null,"abstract":"<div><h3>Background</h3><div>Pre-exposure prophylaxis (PrEP) is effective in preventing HIV. However, engaging people who use drugs (PWUDs) in PrEP services remains challenging due to societal, legal, and structural barriers. This study examined preferences for PrEP services among people who use drugs in Thailand.</div></div><div><h3>Methods</h3><div>We conducted a discrete choice experiment (DCE) using a self-administered paper-based questionnaire from March to August 2024 at Thanyarak Chiang Mai Hospital. PWUDs were identified through hospital records. Random Parameters Logit (RPL) models were used to explore the drivers of PrEP use. RPL models with interactions examined heterogeneity in preferences for PrEP, and Latent Class Models identified subgroups with similar preferences for PrEP.</div></div><div><h3>Results</h3><div>Among 210 respondents, 87 % were male and had a mean age of 33 (±8.5) years. Cost was the most important attribute, followed by location, the friendliness of service providers, the types of PrEP and privacy. PWUDs expressed less preference with PrEP services offered at Key Population Led Health Services (KPLHS), services exclusively catering to PWUDs, with no significant preferences for other locations, interactions with unempathetic or inattentive staff, and services costing 200 THB (US$ 5.6) or 500 THB (US$ 14.1) per month. Compared to their counterparts, those unaware of PrEP were more likely to access the service through TelePrEP, while females preferred accessing PrEP through Key Population Led Health Services. Latent class model revealed that 29 % of respondents tended to favor TelePrEP, while the majority (71 %) were less likely to use PrEP services through Key Population Led Health Services or services provided by unfriendly staff.</div></div><div><h3>Conclusions</h3><div>Diverse PrEP provisions considering service location, the friendliness of service providers, and free access could improve PrEP uptake among people who use drugs. Developing innovative service delivery models that address group-specific preferences is essential.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"143 ","pages":"Article 104913"},"PeriodicalIF":4.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144632557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing drug policies: An assessment of the validity and reliability of the global drug policy index","authors":"David Bewley-Taylor ,&nbsp;Matthew Wall ,&nbsp;Jack Tudor ,&nbsp;Alison Ritter","doi":"10.1016/j.drugpo.2025.104908","DOIUrl":"10.1016/j.drugpo.2025.104908","url":null,"abstract":"<div><h3>Background</h3><div>The Global Drug Policy Index (GDPI) is an instrument that attempts to comparatively evaluate national drug policies at a global scale. This paper assesses the validity and reliability of this new Index, speaking to the wider question of whether such a comparative evaluation can be achieved in a methodologically robust manner.</div></div><div><h3>Method</h3><div>We review the validity of the Index through analysis of the conceptual logic of the GDPI. Construct validity is assessed using Cronbach’s alpha statistics alongside exploratory factor analysis (EFA). The reliability of the Index is assessed using uncertainty analysis where we systematically analyse how Index rankings vary across simulations with randomly perturbed weighting schemes. In addition, we explore the reliability of experts’ assessment of policy implementation, reporting on a common vignette undertaken by all country-expert evaluators.</div></div><div><h3>Results</h3><div>The analysis of conceptual validity is a reproduction of the logic supporting the contention that the project’s underpinning normative document (a report produced by the UN system coordination Task Team on the Implementation of the UN System Common Position on drug-related matters) represents a solid starting point of what will be a sustained, iterative research process to develop a valid conceptual and operational basis for comparative evaluation of national drug policies. The empirical analysis of construct validity reveals that operationalising the Common Position creates a set of variables with a coherent multidimensional structure that is amenable to aggregation into an overall index. While the performance of states under simulations of different weighting schemes was highly consistent, country expert evaluation in developing state codes on policy implementation can be inconsistent, even when they are provided with a common description designed to capture variance on their rating scale. Cronbach’s alpha indicates that the variables encompassed by the GDPI measure a coherent construct, while EFA results provide support for three of the <em>a priori</em> dimensions used in the creation of the Index.</div></div><div><h3>Conclusions</h3><div>We conclude that the GDPI project demonstrates that robust comparative evaluation of drug policy at a global scale is possible. However, we also reveal that this project will necessarily be subject to continuous refinement – especially when it comes to standardising expert country evaluations. We outline practical challenges and suggestions for future work in this direction.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"143 ","pages":"Article 104908"},"PeriodicalIF":4.4,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144606043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the impact of the introduction of generic methadone to the Ontario public drug formulary","authors":"Bisola Hamzat ,&nbsp;Tianru Wang ,&nbsp;Ria Garg ,&nbsp;Anita Iacono ,&nbsp;Mina Tadrous ,&nbsp;Fangyun Wu ,&nbsp;Jennifer Wyman ,&nbsp;Zoë Dodd ,&nbsp;Shauna Pinkerton ,&nbsp;Ashley Smoke ,&nbsp;Tara Gomes","doi":"10.1016/j.drugpo.2025.104918","DOIUrl":"10.1016/j.drugpo.2025.104918","url":null,"abstract":"<div><h3>Background</h3><div>Two new generic methadone products—Jamp-methadone and Odan-methadone—were added to Ontario’s public drug formulary in August 2022 and listed as interchangeable with the brand-name product, Methadose®. Concerns have been raised by people receiving methadone and their prescribers about potential risks of treatment destabilization as a result of switching between methadone-containing products.</div></div><div><h3>Methods</h3><div>We conducted a retrospective population-based time series analysis of weekly methadone claims in Ontario, Canada between January 5, 2017, and March 31, 2023. Using interventional autoregressive integrated moving average models, we assessed the impact of the formulary listing on product market-share, maximum dose dispensed, methadone discontinuation, and opioid toxicities.</div></div><div><h3>Results</h3><div>The market share of Methadose® declined from 99.7 % to 52.3 % between the listing of generic methadone and March 2023, whereas generic products increased from 0.27 % to 40.0 % (Jamp-methadone) and 0.0 % to 7.7 % (Odan-methadone). We observed a significant short-term increase in the percentage of individuals dispensed methadone doses ≥130 mg (+1.30 %; 95 % CI: 0.85 %, 1.76 %) following formulary listing; however the introduction of generic methadone did not result in a significant change in methadone discontinuation among those stabilized (<em>p</em> &gt; 0.5) and not yet stabilized on treatment (<em>p</em> &gt; 0.7) or opioid-related toxicity events (<em>p</em> &gt; 0.1).</div></div><div><h3>Conclusion</h3><div>Our findings did not indicate broad treatment destabilization or increased opioid-related toxicity among methadone recipients in the months following the introduction of generic products. Early notification of formulary changes, phased implementation of the policy, as well as information resources developed for patients and clinicians may have played a role in mitigating potential disruptions for this population.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"143 ","pages":"Article 104918"},"PeriodicalIF":4.4,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144587560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing the estimation of unrecorded alcohol consumption in Chile: a multi-methods study","authors":"Carolina Cornejo ,&nbsp;Deirdre M. Gilmore ,&nbsp;Mariel Mateo Pinones ,&nbsp;Pablo Norambuena Cardenas ,&nbsp;Dirk W. Lachenmeier ,&nbsp;Jürgen Rehm ,&nbsp;Maristela Monteiro ,&nbsp;Alvaro Castillo-Carniglia","doi":"10.1016/j.drugpo.2025.104907","DOIUrl":"10.1016/j.drugpo.2025.104907","url":null,"abstract":"<div><h3>Background</h3><div>Reports of unrecorded alcohol consumption have relied on aggregated and regional information rather than empirical research on national characteristics. This study aims to inform about the Chilean unrecorded alcohol market and the magnitude of unrecorded consumption.</div></div><div><h3>Methods</h3><div>We employed a multi-methods approach with four components: a Delphi panel among experts (<em>n</em> = 21), a survey of people at increased risk of problematic alcohol consumption (<em>n</em> = 138), semi-structured interviews with key stakeholders and alcohol industry informants (<em>n</em> = 12), and chemical analysis of 10 unrecorded alcohol samples.</div></div><div><h3>Results</h3><div>After two rounds of consultations, experts challenged prior estimates of unrecorded alcohol consumption and set per capita levels between 0.05 and 0.5 liters of pure alcohol (0.7 %-8 % of total per capita alcohol consumption), with homemade alcohol as the primary source (31 %). Homemade alcohol consumption was prevalent among individuals at high risk of problematic alcohol use, where clandestine or unlicensed establishments and artisanal producers were primary sources. Informants identified regulatory controls, production traceability, and the affordability of recorded alcohol as factors that limit the unrecorded alcohol market in Chile. Conversely, the availability of raw materials and alcohol taxation were seen as potential threats. Finally, while chemical analyses revealed that some unrecorded alcohol samples exceeded regulatory parameters (e.g., acidity, impurities), all 10 samples were safe for human consumption.</div></div><div><h3>Conclusions</h3><div>Unrecorded alcohol consumption in Chile appears to be lower than previous estimates. A robust surveillance system of the alcohol market will strengthen the institutional capacity to monitor and take actions to prevent harm from recorded and unrecorded alcohol use.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"143 ","pages":"Article 104907"},"PeriodicalIF":4.4,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144581227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Having naloxone when you need it: Factors associated with owning and carrying naloxone among people who use opioids","authors":"Carl A. Latkin ,&nbsp;Lauren Dayton ,&nbsp;Haley Bonneau ,&nbsp;Melissa A. Davey-Rothwell ,&nbsp;Andrew Gaddis ,&nbsp;Oluwaseun Falade-Nwulia","doi":"10.1016/j.drugpo.2025.104914","DOIUrl":"10.1016/j.drugpo.2025.104914","url":null,"abstract":"<div><div>It is critical to have naloxone readily available in the event of an opioid overdose. This study examines the prevalence of owning and carrying naloxone and factors associated with ownership and carriage among people who use opioids in Baltimore, Maryland, from December 2022 to January 2025. Among the 780 community-recruited study participants who were aged 18 years or older and currently used non-prescription opioids, most (78.2 %) reported owning naloxone, with the majority (69.4 %) keeping it at their residence. While 41.8 % of participants reported always having naloxone available when using drugs, 13.5 % never did. Only 27.0 % were carrying it with them at the time of the interview. Frequent heroin/fentanyl use (aOR: 2.07; 95 % CI: 1.36–3.16) and reporting lower difficulty accessing naloxone (aOR: 2.37; 95 % CI: 1.85–3.05) significantly increased the likelihood of owning naloxone. Experiencing homelessness in the past six months (aOR: 2.09; 95 % CI: 1.40–3.12) and perceiving poor neighborhood treatment due to drug use (aOR: 1.27, 95 % CI: 0.1.08–1.49) increased odds of currently carrying naloxone. Although naloxone distribution programs have successfully improved access, substantial gaps remain in consistent naloxone carriage, necessitating targeted interventions addressing barriers to carriage, including drug use stigma.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"143 ","pages":"Article 104914"},"PeriodicalIF":4.4,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144581226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scapegoated communities, shared struggles: A call for solidarity with people who use drugs and queer and trans people","authors":"Kira London-Nadeau ,&nbsp;Christian Barborini ,&nbsp;Rebecca Haines-Saah ,&nbsp;Misha Bazarov ,&nbsp;Sean Bristowe ,&nbsp;Misha Khorkhordina ,&nbsp;Mélodie Lemay-Gaulin ,&nbsp;Catherine Gorka ,&nbsp;Robert-Paul Juster ,&nbsp;Heath D’Alessio ,&nbsp;Nicholas Chadi","doi":"10.1016/j.drugpo.2025.104915","DOIUrl":"10.1016/j.drugpo.2025.104915","url":null,"abstract":"<div><div>Efforts to control, repress, and punish drug use and queer and trans existence are rising as right-wing extremism becomes increasingly mainstream. These connected efforts are seen through the stifling of bodily autonomy and agency using criminal-legal, biomedical and political apparatuses, and have been executed similarly for people who use drugs and queer and trans people alike. This is most notable for those who exist at the intersection of these communities. Both groups have withstood attempts at manufacturing internal hierarchies – always at the expense of those who are already most marginalized – and eradication and erasure from public existence altogether. In this editorial, we argue that these mechanisms of oppression link not only the struggles of queer and trans people and people who use drugs, but also threaten those outside of these groups. As such, this paper is an urgent call to cultivate shared solidarity and action based in theorizing developed by people who use drugs and queer and trans communities. These tools support resistance against oppression not only through the reclamation of bodily autonomy and agency, but also by centering pleasures, desires, dreams, and the ability to imagine ‘utopian’ futures and versions of ourselves.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"143 ","pages":"Article 104915"},"PeriodicalIF":4.4,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144581225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}